Navigation Links
Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients
Date:10/4/2007

- HeFH Patients on Maximally Tolerated Lipid-Lowering Therapies Experienced 46% Further Reductions in LDL-C when Treated with 300 mg/week ISIS 301012

for 13 Weeks - Study Presented in Poster Session Today at DALM Symposium in New York

City - Isis Will Host a Conference Call on Monday, October 8, at 8:00 a.m. E.T.

at http://www.isispharm.com

CARLSBAD, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced new results from its Phase 2 clinical trial of ISIS 301012 in patients with heterozygous familial hypercholesterolemia (HeFH) on stable maximally tolerated lipid-lowering therapies presented in a poster session today at the Drugs Affecting Lipid Metabolism (DALM) XVI International Symposium in New York City. These results will also be presented by Dr. John J.P. Kastelein in an oral session at DALM on Saturday at 3:45 p.m. E.T., and Isis will host a conference call Monday morning at 8:00 a.m. E.T. to further discuss the results.

In a randomized, double-blind, placebo-controlled study, HeFH patients being treated with maximally tolerated lipid-lowering therapies were treated with ISIS 301012 for 6 or 13 weeks. Median baseline LDL-C levels for the dose cohorts ranged from 159 - 204 mg/dL. ISIS 301012 add-on treatment produced potent, dose-dependent, prolonged reductions in all atherogenic lipids, and results were consistent with those reported for patients with routine high cholesterol. Furthermore, this study confirmed that ISIS 301012 treatment results in meaningful reductions in Lp(a), another important predictor of
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  As the Medical Affairs, role has ... in this area are exploring methods to develop strong ... Affairs Consortium at Best Practices, LLC is designed to ... about the key challenges they face. The consortium will ... three virtual roundtable discussions where leaders discuss key findings ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
(Date:8/22/2014)...   Zacks Equity Research highlights Epizyme (Nasdaq: EPZM ... Panera (Nasdaq: PNRA - Free Report ) as the Bear ... Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... - Free Report ). Here is a synopsis of ... : The biotech bull market is far from ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6
... 2011 The U.S. Food and Drug Administration today ... sting by Centruroides scorpions in the United ... Venomous scorpions in the U.S. are mostly ... infants and children, and can cause shortness of breath, ...
... CPHD ) today announced that its executives will ... to participate via webcast. Canaccord Genuity Growth Conference, ... Time Wedbush 2011 Life Sciences Conference, New York, ... Baird 2011 Health Care Conference, New York, NY ...
Cached Medicine Technology:FDA Approves the First Specific Treatment for Scorpion Stings 2Cepheid to Webcast Upcoming Financial Presentations 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Young adults in Athens, ... doing drugs should pick up the phone and call the new ... teen drug addict . , Troubled Teen Athens is a ... ready to finally take the necessary steps to end substance abuse ... are quick to go to friends or peers when really they ...
(Date:8/23/2014)... is almost over and before we know it schools and ... supplies and a new wardrobe might take precedence over the ... spend some time brushing up on bed bug prevention tips. ... populated places,” said Randy Rupert, Bed Bug Team Lead at ... bed bugs to take up residence.” , An already notorious ...
(Date:8/22/2014)... 23, 2014 Recently, Skmen.com, an experienced ... of 2014 bohemian dresses in its online store. Moreover, ... prices, up to 28% off. All the international clients ... August 31, 2014. , The company’s professional online ... to show worldwide customers more the latest information about ...
(Date:8/22/2014)... Recently, UWDress.com, a leading online supplier of ... new range of empire bridesmaid dresses to its ... a summer promotion for these high quality items. All of ... to 75 percent off. , The company’s new items ... efficient assistance on its website. It is true that all ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Millennium Treatment Group ... resulting in a high level of drug use among teenagers. ... fight against drug addiction and work to minimize drug abuse. ... of alcohol and drug addiction in history. According to the ... estimated 23.9 million Americans aged 12 or older—or 9.2 percent ...
Breaking Medicine News(10 mins):Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:Expert Advice for a Bed Bug-Free School Year 2Health News:Cheap Bohemian Dresses Unveiled by Experienced Supplier Skmen.com 2Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... ,Child-Friendly Spaces, to help children cope with ... disaster - Children have ... ... YANGON, Myanmar, May 14 World Vision is addressing the,emotional and physical needs of children ...
... AMDL, Inc. (Amex:,ADL), headquartered in Tustin, ... China, is a vertically integrated specialty,pharmaceutical company. ... AMDL engages in the research, development, manufacture, ... products currently in China. The Company today ...
... St. Louis, PLEASANT GROVE, Utah, May 14 ... pleased to,announce the inclusion of Myo-Med in the new ... Meeting in St. Louis, MO,June 17-21. The company launched ... a favorite with top athletes. Among those endorsing,Myo-Med are ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) announced today that ... the Securities and Exchange,Commission (the "Commission"), as required ... tender offer (the "Offer") by RWD Acquisition I,LLC ... shares of the common,stock of Pharmacyclics, Inc. (the ...
... NARAL Pro-Choice,America endorsed Senator Barack Obama for President., ... Pro-Choice America, based in,Washington D.C., and without the ... NARAL Pro-Choice Pennsylvania will not be issuing ... that this endorsement in,the Democratic primary is premature. ...
... Inc.,(Nasdaq: CPTS ) developer of the Essure(R) ... method available, today reported,that Medi-Cal, California,s state fee-for-service ... or disabled women in California,now have a safe ... not require the general anesthesia, incisions or long ...
Cached Medicine News:Health News:Myanmar: Half a Million Children Affected by Cyclone, Aid Agency Warns 2Health News:Myanmar: Half a Million Children Affected by Cyclone, Aid Agency Warns 3Health News:AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort 2Health News:Toxin-Free Pain Cream to Make First Appearance at Athletic Trainer Event 2Health News:Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission 2Health News:Essure Procedure Now Covered by Medicaid in California 2Health News:Essure Procedure Now Covered by Medicaid in California 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: